リン酸ナトリウム塩の錠剤化における添加剤としての無水リン酸水素カルシウム (フジカリンS^<[O!R]>) と結晶セルロース (アビセルPH-F20^<[O!R]>) の比較

概要

論文の詳細を見る
To improve compliance for pediatric patients with hypophosphatemic vitamin-D resistant rickets or Fanconi syndrome, we studied the preparation of a tablet for sodium phosphate using Fujicalin S^<[O!R]> and Avicel PH-F 20^<[O!R]> as a direct-compression vehicle. Fujicalin S^<[O!R]> and Avicel PH-F 20^<[O!R]> consists of calcium phosphate dibasic and microcrystalline cellulose, respectively. The phosphorus content of the tablet increases by about 10% when using Fujicalin S^<[O!R]> compared with Avicel PH-F 20^<[O!R]> which leads to a reduction in the dosage. The tablets prepared with Fujicalin S^<[O!R]> showed a faster disintegration time and release rate than the tablets prepared with Avicel PH-F 20^<[O!R]>. However, the former showed an incomplete release profile in distilled water because of the insoluble property of calcium phosphate dibasic. On the other hand, the tablet prepared with Avicel PH-F 20^<[O!R]> showed a sustained release of phosphoric acid and completely released the phosphorus in the tablet in distilled water. Phosphorus is reported to be absorbed from the gastrointestinal tract by the carrier-mediated transport. Thus, it was suggested that Avicel PH-F 20^<[O!R]> was a better vehicle than Fujicalin S^<[O!R]> for regarding its clinical use.
日本医療薬学会の論文
1998-12-10